Results 191 to 200 of about 44,923 (207)

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Annals of Oncology, 2013
David Cunningham, Josep Tabernero, S R Park   +2 more
exaly  

Irinotecan

Reactions Weekly, 1999
openaire   +1 more source

Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats

European Journal of Pharmaceutical Sciences, 2009
Sushama Talegaonkar, Roop K Khar, Manu Jaggi   +2 more
exaly  

Irinotecan

Reactions Weekly, 2015
openaire   +1 more source

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma

Annals of Oncology, 2003
V Boige, M Fabbro, E Raymond
exaly  

Irinotecan

Reactions Weekly, 2018
openaire   +1 more source

ST. JOHN'S WORT INTERFERES WITH IRINOTECAN

Ca-A Cancer Journal for Clinicians, 2002
exaly  

Irinotecan and its active metabolite, SN‐38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

Biomedical Chromatography, 2010
Nuggehally Srinivas
exaly  

Irinotecan

Reactions Weekly, 1993
openaire   +1 more source

Irinotecan

Reactions Weekly
openaire   +2 more sources